This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kostapanos, M. S. Articles by Elisaf, M. S. Search for Related Content PubMed PubMed Citation Articles by Kostapanos, M. S. Articles by Elisaf, M. S. Social Bookmarking                         What's this?

Dose-dependent Effect of Rosuvastatin Treatment on HDL-subfraction Phenotype in Patients With Primary Hyperlipidemia

Department of Internal Medicine, University of Ioannina, Ioannina, Greece

Haralampos J. Milionis

Department of Internal Medicine, University of Ioannina, Ioannina, Greece

Theodosios D. Filippatos, MD

Department of Internal Medicine, University of Ioannina, Ioannina, Greece

Leonidas G. Christogiannis, MD

Department of Internal Medicine, University of Ioannina, Ioannina, Greece

Eleni T. Bairaktari

Laboratory of Clinical Chemistry, School of Medicine, University of Ioannina, Ioannina, Greece

Alexandros D. Tselepis

Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece

Moses S. Elisaf, MD, FRSH, FASA

Department of Internal Medicine, University of Ioannina, Ioannina, Greece, egepi{at}cc.uoi.gr

Although the raising effect of rosuvastatin on high-density lipoprotein cholesterol is well-established, there is a paucity of data regarding the effect of this statin on the high-density lipoprotein subfraction phenotype. A total of 150 participants without evidence of cardiovascular disease were randomized to therapeutic lifestyle modification (nonstatin-treated group) or to therapeutic lifestyle modification plus rosuvastatin at 10 mg/d (RSV10 group) or 20 mg/d (RSV20 group). We assessed the effect of rosuvastatin on the cholesterol mass of high-density lipoprotein subfractions at baseline as well as after 12 weeks post-treatment. Rosuvastatin treatment dose-dependently increased the high-density lipoprotein cholesterol (3.4% vs 5.3% in the RSV10 and RSV20 groups, respectively, P = .02). A dose-related rosuvastatin-induced increase in the cholesterol concentration of large high-density lipoprotein particles was also noted (by 11.4% in RSV10 group vs 22.0% in the RSV20 group, P = .01). Rosuvastatin treatment increases the high-density lipoprotein cholesterol by increasing the cholesterol mass only of the larger high-density lipoprotein particles in a dose-dependent manner.

Key Words: HDL subfractions • paraoxonase-1 • lipoprotein-associated phospholipase A2 • rosuvastatin

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 14, No. 1, 5-13 (2009)
DOI: 10.1177/1074248408331031


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?